“…Numerous studies have highlighted the potential for development of melanocortin peptides for modulating the inflammatory response, including the non-selective pan agonists α-MSH and NDP-α-MSH displaying anti-inflammatory, anti-pyretic effects (Ahmed et al, 2013;Patruno et al, 2018), whilst, more selective compounds [DTrp 8 ]-γ-MSH (Kaneva et al, 2012;Patruno et al, 2018), BMS-470539 dihydrochloride (Leoni et al, 2010;Holloway et al, 2015) and AP214 (Montero-Melendez et al, 2011) modulate inflammatory responses in primary chondrocytes (Capsoni et al, 2015), experimental inflammatory arthritis (Patel et al, 2010), and ischaemic reperfusion injury (Holloway et al, 2015), exerting their effects via human melanocortin MC1 and MC3 receptors via adenylate cyclase as demonstrated here and in agreement with Kaneva et al, 2012 for α-MSH and [DTrp 8 ]-γ-MSH, whilst inhibiting proinflammatory, tissue destructive mediators and inducing pro-resolving anti-inflammatory proteins (including IL-10) (Kaneva et al, 2012), HO-1 (Mawatari et al, 2013) and clearance of apoptotic neutrophils (Patruno et al, 2018). In spite of the potential of melanocortin peptides in modulating inflammation elicited by LPS (Sun et al, 2017), no studies to date have evaluated their effect in LPS (0.1 µg/ml) activated chondrocytes.…”